시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 가바펜틴 시장 보고서(2025년)
Gabapentin Global Market Report 2025
상품코드 : 1764323
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,666,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,635,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,605,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가바펜틴 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 이 기간에 예상되는 주요 동향에는 약물전달 시스템의 진보, 가바펜틴의 병용 요법에의 통합, 신경인성 통증에 대한 기술 주도의 연구 개발, 서방형 제제의 진보, 약리 유전체 응용의 개발 등이 있습니다.

간질의 유병률 증가는 향후 몇 년간 가바펜틴 시장의 성장을 이끌 것으로 예측됩니다. 증가는 고령화가 진행되는 것이 주요 원인이며, 고령화가 진행되면 간질 발작을 일으킬 수 있는 신경질환의 위험이 높아집니다. 가바펜틴은 뇌의 비정상적인 신경 활동을 안정시키고 발작을 유발하는 신호를 줄임으로써 뇌전증을 관리하는 데 도움을 줍니다. 칼슘 채널을 표적으로서 작용해, 발작 에피소드를 예방합니다. 질병통제예방센터(CDC)는 2022년에는 18세 이상의 미국 성인 약 290만명이 활동성 간질을 앓고 있다고 보고했습니다.

가바펜틴 시장의 주요 기업은 치료 효과를 향상시키고 신경 질환의 치료 옵션을 넓히기 위해 생물학적 동등성 정제와 같은 신흥 국가 제제의 개발에 주력하고 있습니다. 생물학적 동등성 정제란, 선발품과 동량의 유효 성분을 같은 정도의 속도로 혈중에 보내, 동등한 안전성과 유효성을 확보하는 제네릭 제제입니다. 예를 들어, 2024년 3월 인도 제약 회사인 Strides Pharma Science Limited는 미국 식품의약국(USFDA)의 승인을 받아 600mg과 800mg의 힘을 가진 가바펜틴 정제 USP를 상시했습니다. 이 첨단 가바펜틴 제형은 개선된 생체이용률, 정확한 복용, 편리한 투여를 제공하며, 보다 일관된 치료 결과, 더 나은 증상 조절, 장기 치료에 있어서 사용의 용이성을 지원합니다. 가바펜틴 정제 USP, 600mg은 신뢰할 수 있는 투여와 임상적으로 검증된 효능으로 신경장애성 통증과 부분발작 등 다양한 신경증상을 효과적으로 관리하여 다양한 치료효과를 가져옵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Gabapentin is a prescription drug primarily used to manage nerve pain, epilepsy, and restless legs syndrome. It works by affecting nerve signals and brain chemicals to control seizures and alleviate nerve pain. It is commonly prescribed for nerve-related conditions such as pain from shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and decrease abnormal nerve excitability.

Gabapentin is available in both generic and branded forms. Generic versions contain the same active ingredients and dosages as branded ones, offering a more cost-effective but equally effective treatment option. It comes in multiple dosage forms, including tablets, capsules, and oral solutions, and is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Its primary applications include treatment for epilepsy, neuropathic pain, restless legs syndrome, and additional related conditions.

The gabapentin market research report is one of a series of new reports from The Business Research Company that provides gabapentin market statistics, including the gabapentin industry global market size, regional shares, competitors with the gabapentin market share, detailed gabapentin market segments, market trends, opportunities, and any further data you may need to thrive in the gabapentin industry. This gabapentin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gabapentin market size has grown strongly in recent years. It will grow from $2.78 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of epilepsy, an increase in cases of neuropathic pain, heightened awareness of neurological disorders, a growing elderly population, and the expanded use of generic anticonvulsant medications.

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the rising demand for chronic pain management, increasing approvals of gabapentin formulations, improved healthcare access in developing regions, a greater emphasis on personalized medicine, and the growing burden of neurological disorders. Key trends expected during this period include advancements in drug delivery systems, the integration of gabapentin into combination therapies, technology-driven R&D for neuropathic pain, progress in extended-release formulations, and developments in pharmacogenomics applications.

The rising prevalence of epilepsy is expected to drive the growth of the gabapentin market in the coming years. Epilepsy is a neurological disorder marked by recurring seizures caused by abnormal electrical activity in the brain. The increase in epilepsy cases is largely attributed to the growing aging population, as advancing age heightens the risk of neurological conditions that can lead to seizures. Gabapentin helps manage epilepsy by stabilizing abnormal nerve activity in the brain and reducing signals that trigger seizures. It acts by targeting calcium channels to prevent seizure episodes. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that around 2.9 million U.S. adults aged 18 and older were living with active epilepsy in 2022, reflecting a 1.08% increase compared to 2021. As a result, the growing incidence of epilepsy is contributing to the expansion of the gabapentin market.

Leading companies in the gabapentin market are concentrating on developing advanced formulations, such as bioequivalent tablets, to improve therapeutic efficacy and broaden treatment options for neurological disorders. Bioequivalent tablets are generic formulations that deliver the same amount of active ingredient into the bloodstream at the same rate and extent as the branded version, ensuring equivalent safety and effectiveness. For example, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths following approval from the United States Food & Drug Administration (USFDA), aiming to expand its neurology portfolio in the U.S. market. This advanced gabapentin formulation offers improved bioavailability, accurate dosing, and convenient administration, supporting more consistent therapeutic results, better symptom control, and ease of use in long-term treatment. Gabapentin Tablets USP, 600 mg, provide versatile therapeutic benefits, effectively managing various neurological conditions such as neuropathic pain and partial seizures through dependable dosing and clinically validated efficacy.

In September 2023, Adalvo, a Malta-based pharmaceutical company, partnered with Lotus Pharmaceutical to improve lives by providing accessible and innovative neurological treatments. This collaboration focuses on introducing a convenient, once-daily treatment for postherpetic neuralgia through the launch of Gabapentin ER in South Korea. The initiative aims to address unmet medical needs while strengthening their presence in the neurology market. Lotus Pharmaceutical, based in Taiwan, is the manufacturer of gabapentin extended-release tablets.

Major players in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC.

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gabapentin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gabapentin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gabapentin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gabapentin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gabapentin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gabapentin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Gabapentin Market Characteristics

3. Gabapentin Market Trends And Strategies

4. Gabapentin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gabapentin Growth Analysis And Strategic Analysis Framework

6. Gabapentin Market Segmentation

7. Gabapentin Market Regional And Country Analysis

8. Asia-Pacific Gabapentin Market

9. China Gabapentin Market

10. India Gabapentin Market

11. Japan Gabapentin Market

12. Australia Gabapentin Market

13. Indonesia Gabapentin Market

14. South Korea Gabapentin Market

15. Western Europe Gabapentin Market

16. UK Gabapentin Market

17. Germany Gabapentin Market

18. France Gabapentin Market

19. Italy Gabapentin Market

20. Spain Gabapentin Market

21. Eastern Europe Gabapentin Market

22. Russia Gabapentin Market

23. North America Gabapentin Market

24. USA Gabapentin Market

25. Canada Gabapentin Market

26. South America Gabapentin Market

27. Brazil Gabapentin Market

28. Middle East Gabapentin Market

29. Africa Gabapentin Market

30. Gabapentin Market Competitive Landscape And Company Profiles

31. Gabapentin Market Other Major And Innovative Companies

32. Global Gabapentin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gabapentin Market

34. Recent Developments In The Gabapentin Market

35. Gabapentin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기